Drugs.com - Clinical Trials

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has...

Feb 27, 2025 - 06:43
 0
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has...
Read More

Tags:

Previous Article

Camizestrant Demonstrated Highly Statistically Significant and Clinically Meanin...

Next Article

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for...

Related Posts

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025  0

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in the REDEFINE 2 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Mar 11, 2025  0

NIH Researchers Discover Novel Class of Anti-Malaria Antibodies

NIH Researchers Discover Novel Class of Anti-Malaria An...

Feb 9, 2025  0